Compass Financial Management LLC Purchases New Holdings in Pfizer Inc. $PFE

Compass Financial Management LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 23,884 shares of the biopharmaceutical company’s stock, valued at approximately $578,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in PFE. Handelsbanken Fonder AB boosted its stake in Pfizer by 10.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock worth $59,295,000 after acquiring an additional 232,528 shares during the last quarter. Russell Investments Group Ltd. increased its stake in Pfizer by 15.7% in the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock valued at $132,365,000 after purchasing an additional 745,213 shares in the last quarter. Leuthold Group LLC bought a new stake in Pfizer in the second quarter valued at approximately $4,887,000. North Dakota State Investment Board acquired a new stake in Pfizer in the fourth quarter worth $5,348,000. Finally, Park National Corp OH boosted its position in shares of Pfizer by 332.1% during the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock worth $5,829,000 after purchasing an additional 186,053 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 0.4%

NYSE:PFE opened at $27.97 on Tuesday. The stock has a 50-day simple moving average of $25.34 and a 200 day simple moving average of $26.26. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75. The company has a market cap of $159.41 billion, a PE ratio of 36.80 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Wall Street Analyst Weigh In

Several brokerages recently commented on PFE. JPMorgan Chase & Co. dropped their price objective on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Wolfe Research reiterated an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Monday, July 6th. Finally, UBS Group reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $28.28.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.